Health Care·Biotechnology·$2.2B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.26 | N/A | +218.18% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $0.26 | N/A | +218.18% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Management expressed satisfaction with the EPS results, highlighting their commitment to pipeline development. However, they did not provide specific guidance for future quarters.
We are pleased with our EPS performance this quarter.
Our focus remains on advancing our pipeline.
Biocryst Pharmaceuticals reported a strong earnings per share figure, significantly exceeding expectations. The stock reacted positively, rising by 3.45%, likely driven by the unexpected EPS performance. However, the lack of revenue data and future guidance may leave investors cautious about the company's direction.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
MERCK & CO. INC.
Feb 3, 2009